45 related articles for article (PubMed ID: 10912783)
1. Differentiation of mesothelioma cells is influenced by the expression of proteoglycans.
Dobra K; Andäng M; Syrokou A; Karamanos NK; Hjerpe A
Exp Cell Res; 2000 Jul; 258(1):12-22. PubMed ID: 10912783
[TBL] [Abstract][Full Text] [Related]
2. The Role of RKIP in the Regulation of EMT in the Tumor Microenvironment.
Cessna H; Baritaki S; Zaravinos A; Bonavida B
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230521
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitivity and resistance testing in malignant effusions with focus on primary malignant mesothelioma and metastatic adenocarcinoma.
Szulkin A; Szatmári T; Hjerpe A; Dobra K
Pleura Peritoneum; 2016 Sep; 1(3):119-133. PubMed ID: 30911616
[TBL] [Abstract][Full Text] [Related]
4. Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.
Gharbaran R
Tumour Biol; 2016 Sep; 37(9):11573-11588. PubMed ID: 27317256
[TBL] [Abstract][Full Text] [Related]
5. The Extracellular Matrix in Epithelial Ovarian Cancer - A Piece of a Puzzle.
Cho A; Howell VM; Colvin EK
Front Oncol; 2015; 5():245. PubMed ID: 26579497
[TBL] [Abstract][Full Text] [Related]
6. Syndecans as modulators and potential pharmacological targets in cancer progression.
Barbouri D; Afratis N; Gialeli C; Vynios DH; Theocharis AD; Karamanos NK
Front Oncol; 2014; 4():4. PubMed ID: 24551591
[TBL] [Abstract][Full Text] [Related]
7. The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumors.
Szatmári T; Dobra K
Front Oncol; 2013 Dec; 3():310. PubMed ID: 24392351
[TBL] [Abstract][Full Text] [Related]
8. Heparan sulfate proteoglycans and human breast cancer epithelial cell tumorigenicity.
Okolicsanyi RK; van Wijnen AJ; Cool SM; Stein GS; Griffiths LR; Haupt LM
J Cell Biochem; 2014 May; 115(5):967-76. PubMed ID: 24357546
[TBL] [Abstract][Full Text] [Related]
9. Microenvironment-Dependent Phenotypic Changes in a SCID Mouse Model for Malignant Mesothelioma.
Darai-Ramqvist E; Nilsonne G; Flores-Staino C; Hjerpe A; Dobra K
Front Oncol; 2013; 3():203. PubMed ID: 23951555
[TBL] [Abstract][Full Text] [Related]
10. Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy.
Szulkin A; Nilsonne G; Mundt F; Wasik AM; Souri P; Hjerpe A; Dobra K
PLoS One; 2013; 8(6):e65903. PubMed ID: 23840376
[TBL] [Abstract][Full Text] [Related]
11. Novel genes and pathways modulated by syndecan-1: implications for the proliferation and cell-cycle regulation of malignant mesothelioma cells.
Szatmári T; Mundt F; Heidari-Hamedani G; Zong F; Ferolla E; Alexeyenko A; Hjerpe A; Dobra K
PLoS One; 2012; 7(10):e48091. PubMed ID: 23144729
[TBL] [Abstract][Full Text] [Related]
12. Altered expression of sialylated glycoproteins in breast cancer using hydrazide chemistry and mass spectrometry.
Tian Y; Esteva FJ; Song J; Zhang H
Mol Cell Proteomics; 2012 Jun; 11(6):M111.011403. PubMed ID: 22318369
[TBL] [Abstract][Full Text] [Related]
13. Antithetic roles of proteoglycans in cancer.
Garusi E; Rossi S; Perris R
Cell Mol Life Sci; 2012 Feb; 69(4):553-79. PubMed ID: 21964924
[TBL] [Abstract][Full Text] [Related]
14. Specific syndecan-1 domains regulate mesenchymal tumor cell adhesion, motility and migration.
Zong F; Fthenou E; Mundt F; Szatmári T; Kovalszky I; Szilák L; Brodin D; Tzanakakis G; Hjerpe A; Dobra K
PLoS One; 2011; 6(6):e14816. PubMed ID: 21731601
[TBL] [Abstract][Full Text] [Related]
15. Concise review: mind the gap: challenges in characterizing and quantifying cell- and tissue-based therapies for clinical translation.
Rayment EA; Williams DJ
Stem Cells; 2010 May; 28(5):996-1004. PubMed ID: 20333747
[TBL] [Abstract][Full Text] [Related]
16. Effect of syndecan-1 overexpression on mesenchymal tumour cell proliferation with focus on different functional domains.
Zong F; Fthenou E; Castro J; Péterfia B; Kovalszky I; Szilák L; Tzanakakis G; Dobra K
Cell Prolif; 2010 Feb; 43(1):29-40. PubMed ID: 19840029
[TBL] [Abstract][Full Text] [Related]
17. Syndecan-1 and FGF-2, but not FGF receptor-1, share a common transport route and co-localize with heparanase in the nuclei of mesenchymal tumor cells.
Zong F; Fthenou E; Wolmer N; Hollósi P; Kovalszky I; Szilák L; Mogler C; Nilsonne G; Tzanakakis G; Dobra K
PLoS One; 2009 Oct; 4(10):e7346. PubMed ID: 19802384
[TBL] [Abstract][Full Text] [Related]
18. Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells.
Kousidou OCh; Berdiaki A; Kletsas D; Zafiropoulos A; Theocharis AD; Tzanakakis GN; Karamanos NK
Mol Oncol; 2008 Oct; 2(3):223-32. PubMed ID: 19383343
[TBL] [Abstract][Full Text] [Related]
19. Hyaluronan synthase expression in pleural malignant mesotheliomas.
Kanomata N; Yokose T; Kamijo T; Yonou H; Hasebe T; Itano N; Kimata K; Ochiai A
Virchows Arch; 2005 Mar; 446(3):246-50. PubMed ID: 15731923
[TBL] [Abstract][Full Text] [Related]
20. Excess biglycan causes eyelid malformation by perturbing muscle development and TGF-alpha signaling.
Hayashi Y; Liu CY; Jester JJ; Hayashi M; Wang IJ; Funderburgh JL; Saika S; Roughley PJ; Kao CW; Kao WW
Dev Biol; 2005 Jan; 277(1):222-34. PubMed ID: 15572151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
